Program
islatravir
Also written as “DOR/ISL”, “Islatravir” and “ISL”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Infections, led by 2 companies.
Drug pageIslatravir: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 277 open or running | phase 3since Jan 8, 2020 | Aug 13, 2014 | Aug 10, 2027phase 2 · NCT06891066 |
| Gilead Sciences | 11 open or running | phase 2since Sep 13, 2021 | Sep 13, 2021 | none ahead |
- Named in Merck’s own pipeline as
islatravir + lenacapavir (MK-8591D)
, phase 3, as of Nov 2, 2026 (source). - Named in Merck’s own pipeline as
islatravir + ulonivirine (MK-8591B)
, phase 2, as of Nov 2, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2018Named islatravirINNProposed as its International Nonproprietary Name in WHO's List 120
- Sep 13, 2021First study: phase 2 study in HIV-1 InfectionFirst studyNCT05052996 · 142 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05052996HIV-1 Infection · United States | 2 | Active, not recruiting | Dec 19, 2023 | 142 |
How it is read
Names in the registry
- “DOR/ISL”, 11 entries
- “Islatravir”, 11 entries
- “ISL”, 5 entries
- “Islatravir (ISL)”, 1 entry
- “Doravirine/Islatravir”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 4 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.